AURORA® Opening the World to Cannabis™

Letter from our Executive Chairman and CEO

Dear fellow shareholders,

We are pleased to invite you to the 2026 Annual General Meeting of Shareholders of Aurora Cannabis Inc. ("**Aurora**" or the "**Company**") to be held virtually on Friday, August 7, 2026 at 1:00 pm Eastern Time (the "**Meeting**"). Meeting details, including instructions on how to vote and submit questions, can be found within the accompanying Information Circular. As always, we look forward to your participation.

First and foremost, on behalf of the Board and the entire Aurora team, I would like to offer a sincere thank you to our shareholders for your trust and support. Fiscal 2026 was a standout year for the Company, including achieving several financial milestones. We achieved record annual global medical cannabis net revenue of $289 million, representing 18% year-over-year growth and record adjusted EBITDA(1) growth of 32% year-over-year reaching $54 million. Our growth in key international markets also reached record revenue levels at $177 million, representing a 29% increase year-over-year, and we ended the year with a cash balance of $165 million and a debt-free business, giving us the flexibility to invest in our growth.

Aurora has focused on medical cannabis as the most promising and profitable industry segment for nearly a decade. We have established a strong competitive position globally by building deep regulatory capabilities, and world-class cannabis genetics, supported by an extensive global network of GMP manufacturing facilities. Aurora has consistently demonstrated excellence in commercial execution in profitable and accessible markets. This focused approach has secured our leadership in four of the largest nationally legal medical cannabis markets - Canada, Germany, Poland and Australia. Most recently, we accelerated our global leadership through the acquisition of Safari Flower Company, marking an important milestone as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market.

As a global medical cannabis leader operating in 12 countries, the recent reclassification of medical cannabis from Schedule I to Schedule III in the United States is an exciting development for the industry and reflects what we've long understood – medical cannabis has clear value for patients. We support reforms that recognize cannabis as medicine – an approach that has become the hallmark of smart health policy globally. Importantly, this shift signals the integration of cannabis into drug policy and science frameworks, aligning with global standards and regulatory compliance. We look forward to working with regulators and industry stakeholders as this transition advances and new pathways for research, innovation and responsible market development emerge.

Aurora has built one of the most attractive global medical-cannabis growth platforms in the world, anchored by a sizable global footprint. Our performance in fiscal year 2026 demonstrated the strength, durability and scalability of our operating model, developed and executed by a talented global team. While the operating and competitive environment is evolving, we are taking decisive action now to lay the foundation for our next phase of growth. We plan to leverage the same capabilities that built our leadership position so that we can ultimately generate new records for revenue and adjusted EBITDA (1).

The targeted investments we are making today in market share, GMP capacity, product innovation, and international expansion are designed to position Aurora among the select few companies equipped to navigate increasing GMP standards and deliver sustained long-term growth.

I encourage you to click here or visit the investor section of our website (**AuroraMJ.com**) to watch a brief message from me and Simona King, our CFO, as we reflect on fiscal 2026 and the future for Aurora. I look forward to providing further updates on our progress as we continue to advance our global leadership and deliver consistent, high-quality cannabis products to patients worldwide in pursuit of our purpose of **Opening the World to Cannabis™.**

Your vote is important to us. Thank you for your trust and support.

Sincerely,

Miguel Martin

Miguel Martin
Executive Chairman and Chief Executive Officer

(1) This is a non-GAAP financial measure, which is intended to supplement, not substitute, comparable GAAP financial measures. This measure is not a standardized financial measure under the financial reporting framework used to prepare our financials and might not be comparable to similar financial measures disclosed by other issuers. This term and the reconciliation to the most comparable GAAP measure are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the FY26 Q4 MD&A, which can be found on SEDAR+ and our website.